Aligos Therapeutics (ALGS) EBT Growth (3y) (2022 - 2026)
Powered by 
Analysis
Aligos Therapeutics (ALGS) EBT Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 19.70% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -103.74% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 6.22% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 12.16% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 103.79% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 24.03% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 38.36% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -42.82% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Aligos Therapeutics | 54.92 Mn | 24.48 Mn | - | 27.50% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.50% |
| Mar 31, 2026 | 0.28% |
| Dec 31, 2025 | 3.13% |
| Sep 30, 2025 | -19.04% |
| Jun 30, 2025 | 7.61% |
| Mar 31, 2025 | 47.56% |
| Dec 31, 2024 | -29.55% |
| Sep 30, 2024 | 16.56% |
| Jun 30, 2024 | 29.59% |
| Mar 31, 2024 | -8.04% |
| Dec 31, 2023 | 6.54% |
| Sep 30, 2023 | 18.52% |
| Jun 30, 2023 | 4.73% |
| Mar 31, 2023 | -4.59% |
| Dec 31, 2022 | -6.46% |
| Sep 30, 2022 | -9.93% |